New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies Book

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

  • Author : Anonim
  • Publisher : Academic Press
  • Release Date : 2020-11-01
  • Genre: Business & Economics
  • Pages : 250
  • ISBN 10 : 9780128167373

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies Excerpt :

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

High Dose Chemotherapy Book

High Dose Chemotherapy

  • Author : Paul C. Lorigan
  • Publisher : CRC Press
  • Release Date : 2002-04-11
  • Genre: Medical
  • Pages : 336
  • ISBN 10 : 9058232328

High Dose Chemotherapy Excerpt :

This text presents an overview of the basic science and principles of high dose chemotherapy, current state-of-the-art techniques and future developments such as gene therapy. The main section of the book is disease-based, setting the scientific principles within a clinical context and reviewing the application of high dose therapy in specific diseases. Additional sections discuss supportive care and long-term complications. High Dose Chemotherapy is directed at hematologists, clinical and medical oncologists in training or with an interest, rather than direct involvement, in the field.

Novel Sensitizing Agents for Therapeutic Anti EGFR Antibodies Book

Novel Sensitizing Agents for Therapeutic Anti EGFR Antibodies

  • Author : Shi Hu
  • Publisher : Academic Press
  • Release Date : 2022-11-25
  • Genre: Science
  • Pages : 258
  • ISBN 10 : 9780128215852

Novel Sensitizing Agents for Therapeutic Anti EGFR Antibodies Excerpt :

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists. Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance. Presents detailed descriptions on the history, chemistry, mechanism of action, structure-function relationships, pharmacology, side effects, dosing and formulation of new sensitizers to anti-EGFR antibodies Provides molecular structures for all novel anticancer drugs, along with strategies to overcome resistance to anti-EGFR antibodies Encompasses up-to-date information on the cancer drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in emerging areas of precision medicine

Resistance to Targeted Therapies in Lymphomas Book

Resistance to Targeted Therapies in Lymphomas

  • Author : Ana C. Xavier
  • Publisher : Springer Nature
  • Release Date : 2019-09-13
  • Genre: Medical
  • Pages : 210
  • ISBN 10 : 9783030244248

Resistance to Targeted Therapies in Lymphomas Excerpt :

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

Advances in Lymphoma Research Book

Advances in Lymphoma Research

  • Author : Fernando Cabanillas
  • Publisher : Springer Science & Business Media
  • Release Date : 2012-12-06
  • Genre: Medical
  • Pages : 169
  • ISBN 10 : 9781461541295

Advances in Lymphoma Research Excerpt :

Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.

The Lymphoid Neoplasms 3ed Book

The Lymphoid Neoplasms 3ed

  • Author : Ian Magrath
  • Publisher : CRC Press
  • Release Date : 2010-07-30
  • Genre: Medical
  • Pages : 1689
  • ISBN 10 : 9781444113228

The Lymphoid Neoplasms 3ed Excerpt :

This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors synthesise for the reader apsects of current knowledge and likely future developments, and direct them to the appropriate resources should they wish to pursue particular avenues of scientific or literature research.

Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy Book

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

  • Author : Patrik Andersson
  • Publisher : Frontiers Media SA
  • Release Date : 2019-12-27
  • Genre: Uncategoriezed
  • Pages : 316
  • ISBN 10 : 9782889631612

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy Excerpt :

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Goldman s Cecil Medicine Expert Consult Premium Edition    Enhanced Online Features and Print  Single Volume 24 Book

Goldman s Cecil Medicine Expert Consult Premium Edition Enhanced Online Features and Print Single Volume 24

  • Author : Russell La Fayette Cecil
  • Publisher : Elsevier Health Sciences
  • Release Date : 2012-01-01
  • Genre: Health & Fitness
  • Pages : 2848
  • ISBN 10 : 9781437716047

Goldman s Cecil Medicine Expert Consult Premium Edition Enhanced Online Features and Print Single Volume 24 Excerpt :

Since 1927, Goldman-Cecil Medicine has been the world's most influential internal medicine resource. In the ground-breaking 25th edition, your original purchase ensures you will be up-to-date without the need for a subscription. Through the new, more powerful Expert Consult eBook platform, this "living text" provides continuous updates that will integrate the latest research, guidelines, and treatments into each chapter, ensuring that the content is as current as the day this edition was first published. Goldman-Cecil Medicine offers definitive, unbiased guidance on the evaluation and management of every medical condition, presented by a veritable "Who's Who" of modern medicine. A practical, straightforward style; templated organization; evidence-based references; and robust interactive content combine to make this dynamic resource quite simply the fastest and best place to find all of the authoritative, state-of-the-art clinical answers you need. "The content is superb, authoritative and not surprisingly very up to date." Reviewed by: Dr Harry Brown, on behalf of Glycosmedia Date: July 2015 Expert Consult eBook version included with print purchase: Access continuous updates from Editor Lee Goldman, MD, who thoroughly reviews internal medicine and specialty journals, updating online content to reflect the latest guidelines and translating that evidence into treatment. Interactive Q&A section features over 1,500 board-style questions and answers to aid in preparing for certification or recertification exams. Outstanding supplementary tools include figures, tables, videos, heart and lung sounds, treatment and management algorithms, fully integrated references, and thousands of illustrations and full-color photos. Search all of the text, figures, supplementary material, and references from the book on a variety of devices and at no additional cost - Expert Consult access is included with this title! Practical, bulleted, highly templated text with easy-to-use features i

Neoplastic Diseases of the Blood Book

Neoplastic Diseases of the Blood

  • Author : Peter H. Wiernik
  • Publisher : Springer Science & Business Media
  • Release Date : 2012-09-22
  • Genre: Medical
  • Pages : 1431
  • ISBN 10 : 9781461437642

Neoplastic Diseases of the Blood Excerpt :

Neoplastic Diseases of the Blood integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. The book is divided into five major sections, with the first four covering the spectrum of hematologic neoplasia— Chronic Leukemias and Related Disorders , Acute Leukemias, Myeloma and Related Disorders, and Lymphomas. The fifth section covers a variety of topics in supportive care. Now in its fifth edition, this classic and invaluable text brings together a team of internationally renowned experts and offers in-depth coverage of the complex interface between diagnosis and therapy. Chapters feature an accessible and easy-to-read layout and provide updates on the tremendous progress made in the last decade in the understanding of the nature of hematologic malignancies and their treatment. An authoritative and indispensable resource for students, trainees, and clinicians, this fifth edition is sure to distinguish itself as the definitive reference on this topic.

Non Hodgkin Lymphoma Book

Non Hodgkin Lymphoma

  • Author : Andrew M. Evens
  • Publisher : Springer
  • Release Date : 2015-02-06
  • Genre: Medical
  • Pages : 344
  • ISBN 10 : 9783319131504

Non Hodgkin Lymphoma Excerpt :

This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.

Drug Benefits and Risks Book

Drug Benefits and Risks

  • Author : C.J. van Boxtel
  • Publisher : IOS Press
  • Release Date : 2008-08-06
  • Genre: Medical
  • Pages : 846
  • ISBN 10 : 9781607503453

Drug Benefits and Risks Excerpt :

This updated and revised 2nd edition of Drug Benefits and Risks is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs, but in this context also highlighting the social impact which drugs have in modern societies. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined. For this purpose the book covers general clinical pharmacology, pharmacology of various drug groups and the treatments specific to various diseases; the book gives guidance on how doctors should act so that drugs can be used effectively and safely; and it encourages the rational use of drugs in society. This publication brings together a large amount of excellent content that will be invaluable for anyone working within, or associated with, the field of clinical pharmacology and pharmacotherapy - undergraduates, postgraduates, regulatory authorities and the pharmaceutical industry.

NK Cells in Cancer Immunotherapy  Successes and Challenges Book

NK Cells in Cancer Immunotherapy Successes and Challenges

  • Author : Anahid Jewett
  • Publisher : Academic Press
  • Release Date : 2022-12-06
  • Genre: Science
  • Pages : 496
  • ISBN 10 : 9780128226261

NK Cells in Cancer Immunotherapy Successes and Challenges Excerpt :

NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients. Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective. Covers CAR/T and CAR/NK and adoptive NK cell therapy with and without T cell therapies Discusses basic biology of NK cells and mouse models of human cancers and the role of NK cells in metastatic cancer and in cancer stem cells Encompasses information on combination therapies using check point inhibition, adoptive transfer of cytotoxic effector cells, chemotherapeutic drugs and activating and inhibitory antibodies

Principles of Cancer Biotherapy Book

Principles of Cancer Biotherapy

  • Author : Robert K. Oldham
  • Publisher : Springer Science & Business Media
  • Release Date : 2009-08-29
  • Genre: Medical
  • Pages : 742
  • ISBN 10 : 9048122899

Principles of Cancer Biotherapy Excerpt :

At the time of the first edition of Principles of Cancer Biotherapy in 1987, this book represented the first comprehensive textbook on biological therapy. In 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the therapeutic value of these new approaches. By 2003 and the fourth edition, it was generally agreed that biopharmaceuticals were producing major opportunities for new cancer therapies. Cancer biotherapy has now truly matured into the fourth modality of cancer treatment. This fifth revised edition describes the tremendous progress that has been made in recent years using biologicals in cancer treatment. This book summarizes an evolving science and a rapidly changing medical practice in biotherapy. In this new millennium, it is now possible to envision a much more diversified system of cancer research and treatment that will afford greater opportunities for a patient’s personalized cancer treatment. This was first envisioned in the 1987 initial edition of this textbook and is now a “new” and popular approach to cancer treatment. Some forms of cancer biotherapy use the strategy of tumor stabilization and control through continued biological therapy, akin to the use of insulin in the treatment of diabetes. This textbook illustrates new methods of thinking and new strategies for control of cancer. It is always difficult to move from past dogma to future opportunity, but this fifth edition of Principles of Cancer Biotherapy illustrates why it is so important to the patients for researchers and clinicians to explore and quickly apply these new opportunities in cancer biotherapy.

Methods of Cancer Diagnosis  Therapy  and Prognosis Book

Methods of Cancer Diagnosis Therapy and Prognosis

  • Author : M. A. Hayat
  • Publisher : Springer Science & Business Media
  • Release Date : 2010-04-07
  • Genre: Medical
  • Pages : 476
  • ISBN 10 : 9048131863

Methods of Cancer Diagnosis Therapy and Prognosis Excerpt :

There are more than 100 types of cancers In Part II, head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500,000. These with cancer every year, and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma, salivary gland tumors, tons- the year 2020. In 2005, 7. 6 million peo- lar cancer, tongue cancer, nasopharyngeal ple died of cancer, that is, 13% of the 58 carcinoma, and retinoblastoma, which are million deaths worldwide. It is estimated detailed. In Part III, diagnosis, therapy, and that 9 million people will die from can- prognosis of thyroid carcinoma are d- cer worldwide in 2015 and 11. 4 million cussed. The global number of new cases of will die in 2030. More than 70% of all thyroid cancer is ~141,000, and the number cancer deaths occur in low and middle of worldwide thyroid mortalities is ~35,375. income countries. These statistics underlie The number of new cases of this cancer in the fact that cancer is the deadliest of all the United States is ~33,550. Molecular human diseases. The enormity of the glo- genetics of thyroid cancer, gene expr- bal healthcare costs as a result of cancer sion markers for diagnosis, papillary t- cannot be overemphasized.